Phase 3 N=147 Randomized Double-blind Treatment

SSRI and Buprenorphine

Opiate Dependence · Depression

Bottom Line

View on ClinicalTrials.gov: NCT00475878 ↗

Enrolled (actual)

147

Serious AEs

0.7%

Results posted

Apr 2012

Primary outcome: Primary: Percentage of Participants Who Dropped Out of Buprenorphine Treatment — 33.3; 44.0 percentage of participants — p=.19

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: escitalopram (Drug); placebo (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Butler Hospital
Primary completion: Sep 2009

Outcome Measures

Outcome	Result	p-value
PRIMARY Percentage of Participants Who Dropped Out of Buprenorphine Treatment	33.3; 44.0	.19
SECONDARY Depressive Symptoms	12.31; 11.35	.18

Summary

This study is designed to test whether treatment of depressive symptoms using escitalopram improves adherence to Buprenorphine and reduces symptoms of depression for individuals receiving Buprenorphine through their medical provider.

Eligibility Criteria

Inclusion Criteria

opiate dependence
Ham-D > 14

Exclusion Criteria

no psychiatric contraindications to using escitalopram
no medical contraindications to using escitalopram
methadone dose < 30
no current SSRI use

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00475878). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.